IRG1-IN-1, an itaconic acid derivative, inhibits Immune Response Gene 1 (IRG1) activity and is suitable for cancer, inflammation, and autoimmune disease research.

IRG1-IN-1 (0.5 mM; 1 mM) partially inhibits the proliferation of C-IRG1-9 rat glioma cells [1].
IRG1-IN-1 (0.5 mM; 2 mM) reduces the production of itaconic acid and the secretion of TNFα from human monocyte-derived macrophages (hMDMs) stimulated with LPS [1].IRG1-IN-1 (10μM) shows a decrease in trimethylation of histone 3 at lysine 4 (H3K4me3) in CR-activated hCD8+ T cells [1].
IRG1-IN-1 (10 nM) increases the proliferation of TCR-activated hCD8+ T cells [1].

IRG1-IN-1 administered intraperitoneally at a dose of 0.2 mg/kg for 27 days demonstrates a significant anti-tumor effect in C57BL/6 mice [1].